Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891

Paul C. Rogers, Thomas A. Olson, John W. Cullen, Deborah F. Billmire, Neyssa Marina, Frederick Rescorla, Mary M. Davis, Wendy B. London, Stephen J. Latter, Roger H. Giller, Barbara Cushing

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Purpose: To determine whether children with localized gonadal malignant germ cell tumors (MGCT) stage II testicular and stages I and II ovarian treated with four cycles of standard-dose cisplatin combined with etoposide and low-dose bleomycin (PEB) have an event-free survival (EFS) of at least 85% without significant toxicity. Patients and Methods Between May 1990 and July 1995, eligible pediatric patients with stage II or recurrent from stage I (as a stage II) testicular MGCT and stages I and II ovarian MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study. PEB chemotherapy consisted of bleomycin 15 U/m2 on day 1, cisplatin 20 mg/m 2/d on days 1 to 5, and etoposide 100 mg/m2/d on days 1 to 5. Patients received four cycles of therapy at 21-day intervals. Results Seventy-four patients with a median age of 10.5 years (range, 8.7 months to 16.7 years) were enrolled. Primary sites included: stage II testicular (n = 17), stage I ovarian (n = 41), and stage II ovarian MGCT (n = 16). Treatment with standard PEB resulted in 6-year EFS of 95% and overall survival (OS) of 95.7%. EFS and OS by primary site were as follows: stage II testicular, 100% and 100%; stage I ovarian, 95.1% and 95.1%; and stage II ovarian, 87.5% and 93.8%, respectively. Two patients died from recurrent disease, and one patient died of secondary acute myelocytic leukemia. Infrequent grade 3 to 4 hematologic toxicity was reported. No grade 3 to 4 renal, pulmonary, or ototoxicity was observed. Conclusion Combination chemotherapy with PEB results in excellent EFS and OS with minimal toxicity in children and adolescents with localized gonadal MGCT.

Original languageEnglish (US)
Pages (from-to)3563-3569
Number of pages7
JournalJournal of Clinical Oncology
Volume22
Issue number17
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Pediatrics
Disease-Free Survival
Neoplasms
Bleomycin
Etoposide
Cisplatin
Survival
Therapeutics
Combination Drug Therapy
Acute Myeloid Leukemia
Kidney
Drug Therapy
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors : A Pediatric Intergroup study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891. / Rogers, Paul C.; Olson, Thomas A.; Cullen, John W.; Billmire, Deborah F.; Marina, Neyssa; Rescorla, Frederick; Davis, Mary M.; London, Wendy B.; Latter, Stephen J.; Giller, Roger H.; Cushing, Barbara.

In: Journal of Clinical Oncology, Vol. 22, No. 17, 2004, p. 3563-3569.

Research output: Contribution to journalArticle

Rogers, Paul C. ; Olson, Thomas A. ; Cullen, John W. ; Billmire, Deborah F. ; Marina, Neyssa ; Rescorla, Frederick ; Davis, Mary M. ; London, Wendy B. ; Latter, Stephen J. ; Giller, Roger H. ; Cushing, Barbara. / Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors : A Pediatric Intergroup study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 17. pp. 3563-3569.
@article{b6c96fd011374ed6bfb8eada98d18fa3,
title = "Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891",
abstract = "Purpose: To determine whether children with localized gonadal malignant germ cell tumors (MGCT) stage II testicular and stages I and II ovarian treated with four cycles of standard-dose cisplatin combined with etoposide and low-dose bleomycin (PEB) have an event-free survival (EFS) of at least 85{\%} without significant toxicity. Patients and Methods Between May 1990 and July 1995, eligible pediatric patients with stage II or recurrent from stage I (as a stage II) testicular MGCT and stages I and II ovarian MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study. PEB chemotherapy consisted of bleomycin 15 U/m2 on day 1, cisplatin 20 mg/m 2/d on days 1 to 5, and etoposide 100 mg/m2/d on days 1 to 5. Patients received four cycles of therapy at 21-day intervals. Results Seventy-four patients with a median age of 10.5 years (range, 8.7 months to 16.7 years) were enrolled. Primary sites included: stage II testicular (n = 17), stage I ovarian (n = 41), and stage II ovarian MGCT (n = 16). Treatment with standard PEB resulted in 6-year EFS of 95{\%} and overall survival (OS) of 95.7{\%}. EFS and OS by primary site were as follows: stage II testicular, 100{\%} and 100{\%}; stage I ovarian, 95.1{\%} and 95.1{\%}; and stage II ovarian, 87.5{\%} and 93.8{\%}, respectively. Two patients died from recurrent disease, and one patient died of secondary acute myelocytic leukemia. Infrequent grade 3 to 4 hematologic toxicity was reported. No grade 3 to 4 renal, pulmonary, or ototoxicity was observed. Conclusion Combination chemotherapy with PEB results in excellent EFS and OS with minimal toxicity in children and adolescents with localized gonadal MGCT.",
author = "Rogers, {Paul C.} and Olson, {Thomas A.} and Cullen, {John W.} and Billmire, {Deborah F.} and Neyssa Marina and Frederick Rescorla and Davis, {Mary M.} and London, {Wendy B.} and Latter, {Stephen J.} and Giller, {Roger H.} and Barbara Cushing",
year = "2004",
doi = "10.1200/JCO.2004.01.006",
language = "English (US)",
volume = "22",
pages = "3563--3569",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "17",

}

TY - JOUR

T1 - Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors

T2 - A Pediatric Intergroup study - Pediatric Oncology Group 9048 and Children's Cancer Group 8891

AU - Rogers, Paul C.

AU - Olson, Thomas A.

AU - Cullen, John W.

AU - Billmire, Deborah F.

AU - Marina, Neyssa

AU - Rescorla, Frederick

AU - Davis, Mary M.

AU - London, Wendy B.

AU - Latter, Stephen J.

AU - Giller, Roger H.

AU - Cushing, Barbara

PY - 2004

Y1 - 2004

N2 - Purpose: To determine whether children with localized gonadal malignant germ cell tumors (MGCT) stage II testicular and stages I and II ovarian treated with four cycles of standard-dose cisplatin combined with etoposide and low-dose bleomycin (PEB) have an event-free survival (EFS) of at least 85% without significant toxicity. Patients and Methods Between May 1990 and July 1995, eligible pediatric patients with stage II or recurrent from stage I (as a stage II) testicular MGCT and stages I and II ovarian MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study. PEB chemotherapy consisted of bleomycin 15 U/m2 on day 1, cisplatin 20 mg/m 2/d on days 1 to 5, and etoposide 100 mg/m2/d on days 1 to 5. Patients received four cycles of therapy at 21-day intervals. Results Seventy-four patients with a median age of 10.5 years (range, 8.7 months to 16.7 years) were enrolled. Primary sites included: stage II testicular (n = 17), stage I ovarian (n = 41), and stage II ovarian MGCT (n = 16). Treatment with standard PEB resulted in 6-year EFS of 95% and overall survival (OS) of 95.7%. EFS and OS by primary site were as follows: stage II testicular, 100% and 100%; stage I ovarian, 95.1% and 95.1%; and stage II ovarian, 87.5% and 93.8%, respectively. Two patients died from recurrent disease, and one patient died of secondary acute myelocytic leukemia. Infrequent grade 3 to 4 hematologic toxicity was reported. No grade 3 to 4 renal, pulmonary, or ototoxicity was observed. Conclusion Combination chemotherapy with PEB results in excellent EFS and OS with minimal toxicity in children and adolescents with localized gonadal MGCT.

AB - Purpose: To determine whether children with localized gonadal malignant germ cell tumors (MGCT) stage II testicular and stages I and II ovarian treated with four cycles of standard-dose cisplatin combined with etoposide and low-dose bleomycin (PEB) have an event-free survival (EFS) of at least 85% without significant toxicity. Patients and Methods Between May 1990 and July 1995, eligible pediatric patients with stage II or recurrent from stage I (as a stage II) testicular MGCT and stages I and II ovarian MGCT were enrolled onto this Pediatric Oncology Group and Children's Cancer Group study. PEB chemotherapy consisted of bleomycin 15 U/m2 on day 1, cisplatin 20 mg/m 2/d on days 1 to 5, and etoposide 100 mg/m2/d on days 1 to 5. Patients received four cycles of therapy at 21-day intervals. Results Seventy-four patients with a median age of 10.5 years (range, 8.7 months to 16.7 years) were enrolled. Primary sites included: stage II testicular (n = 17), stage I ovarian (n = 41), and stage II ovarian MGCT (n = 16). Treatment with standard PEB resulted in 6-year EFS of 95% and overall survival (OS) of 95.7%. EFS and OS by primary site were as follows: stage II testicular, 100% and 100%; stage I ovarian, 95.1% and 95.1%; and stage II ovarian, 87.5% and 93.8%, respectively. Two patients died from recurrent disease, and one patient died of secondary acute myelocytic leukemia. Infrequent grade 3 to 4 hematologic toxicity was reported. No grade 3 to 4 renal, pulmonary, or ototoxicity was observed. Conclusion Combination chemotherapy with PEB results in excellent EFS and OS with minimal toxicity in children and adolescents with localized gonadal MGCT.

UR - http://www.scopus.com/inward/record.url?scp=4444279138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444279138&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.01.006

DO - 10.1200/JCO.2004.01.006

M3 - Article

C2 - 15337806

AN - SCOPUS:4444279138

VL - 22

SP - 3563

EP - 3569

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -